Methods of treating hematologic cancers
The present application relates to treatment of hematologic cancers, which treatments can include, e.g., administration of a purine nucleoside phosphorylase (PNP) inhibitor, an alkylating agent and/or an anti-CD20 agent, and related compositions and kits.
1. A method of treating a hematologic cancer in a subject comprising the steps of:
a. administering to the subject an effective amount Forodesine; and
b. administering to the subject an effective amount of an alkylating agent, wherein the administration of Forodesine and the alkylating agent results in a synergistic effect, wherein the alkylating agent is Bendamustine and the hematologic cancer is resistant to Bendamustine and Fludarabine.
2. The method of claim 1 , wherein Forodesine and the alkylating agent are administered concurrently.
3. The method of claim 1 , wherein Forodesine and the alkylating agent are administered sequentially.
4. The method of claim 1 , wherein the alkylating agent is administered one or more times prior to administration of Forodesine.
5. The method of claim 1 , wherein the hematologic cancer is non-Hodgkin's lymphoma, chronic lymphocytic leukemia, or acute lymphoblastic leukemia.
6. The method of claim 1 , wherein the hematologic cancer contains a p53 deletion.